九典制药(300705) - 2024 Q1 - 季度财报

Financial Performance - Total operating revenue for the current period reached ¥590,896,382.47, an increase of 17.74% compared to ¥501,873,303.51 in the previous period[32]. - Net profit attributable to shareholders was ¥125,669,473.12, reflecting a significant growth of 63.44% from ¥76,890,546.67 in the same period last year[32]. - Basic earnings per share rose to ¥0.36, a 63.64% increase compared to ¥0.22 in the prior period[32]. - The net profit attributable to the parent company for Q1 2024 was CNY 125,669,473.12, an increase from CNY 76,890,546.67 in Q1 2023, representing a growth of 63.6%[45]. - Basic and diluted earnings per share for Q1 2024 were CNY 0.36, compared to CNY 0.22 in Q1 2023, reflecting a 63.6% increase[45]. Cash Flow - Net cash flow from operating activities rose by 142.47% to CNY 238,171,199.76, attributed to increased sales collections[7]. - The cash flow from operating activities was not explicitly detailed, but the net increase in cash and cash equivalents was CNY 108,848,481.01 for Q1 2024, compared to CNY 11,273,537.24 in Q1 2023[49]. - Net cash flow from operating activities was $238,171,199.76, significantly up from $98,228,739.03 year-over-year[52]. - The company's cash flow from financing activities decreased by 106.27% to CNY -2,949,833.82, mainly due to a reduction in project loans[7]. - The net cash flow from financing activities for Q1 2024 was negative at CNY -2,949,833.82, compared to a positive CNY 47,040,354.71 in Q1 2023[49]. Assets and Liabilities - The total assets of the company reached approximately 2.96 billion RMB, up from 2.87 billion RMB, indicating a growth of about 3.74%[23]. - Total assets at the end of the reporting period were ¥2,958,277,158.44, representing a 3.03% increase from ¥2,871,199,809.89 at the end of the previous year[32]. - Total liabilities decreased to CNY 851,455,082.07 in Q1 2024 from CNY 897,929,910.35 in Q1 2023, a reduction of approximately 5.2%[41]. - The total equity attributable to the parent company increased to CNY 2,106,822,076.37 in Q1 2024 from CNY 1,973,269,899.54 in Q1 2023, marking a growth of about 6.7%[41]. - The company's long-term borrowings increased to CNY 66,451,952.40 in Q1 2024 from CNY 58,830,636.97 in Q1 2023, representing an increase of approximately 12.5%[41]. Income and Expenses - The company's income tax expense increased by 122.19% to CNY 19,960,829.75, reflecting higher profits[7]. - Financial expenses increased significantly by 4390.10% to CNY 4,032,529.95, mainly due to convertible bond interest[7]. - Research and development expenses for the current period were ¥40,928,107.97, slightly down from ¥42,597,978.69 in the previous period[32]. - The company reported a significant increase in other income, which rose to ¥24,872,049.39 from ¥9,223,493.74 in the previous period[32]. Investments and Growth Strategy - The company plans to expand its product offerings, including new medical and health products, as part of its growth strategy[21]. - The company is focusing on research and development of new technologies and products to enhance its market position[21]. - The company is exploring potential mergers and acquisitions to enhance its market presence and operational capabilities[21]. Changes in Financial Position - The total amount of trade financial assets increased by 44.98% to CNY 130,906,550.68, driven by an increase in financial products[5]. - The company reported a significant increase in trading financial assets from approximately 90.29 million RMB to 130.91 million RMB, a growth of about 45%[23]. - The company's other receivables increased by 40.04% to CNY 5,207,443.44, mainly due to an increase in petty cash[5]. - The accounts receivable financing decreased by 34.90% to CNY 31,193,615.47, due to the endorsement transfer of notes[5]. - The company's accounts receivable decreased from approximately 545.57 million RMB to 432.77 million RMB, a decline of about 20.65%[23].